Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.80
PODD's Cash to Debt is ranked lower than
63% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. PODD: 0.80 )
Ranked among companies with meaningful Cash to Debt only.
PODD' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.17 Max: N/A
Current: 0.8
Equity to Asset 0.19
PODD's Equity to Asset is ranked lower than
93% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. PODD: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
PODD' s Equity to Asset Range Over the Past 10 Years
Min: -2.37  Med: 0.27 Max: 0.73
Current: 0.19
-2.37
0.73
F-Score: 3
Z-Score: 2.91
M-Score: -3.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -13.14
PODD's Operating margin (%) is ranked lower than
73% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. PODD: -13.14 )
Ranked among companies with meaningful Operating margin (%) only.
PODD' s Operating margin (%) Range Over the Past 10 Years
Min: -43010  Med: -64.87 Max: -4.26
Current: -13.14
-43010
-4.26
Net-margin (%) -17.39
PODD's Net-margin (%) is ranked lower than
72% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. PODD: -17.39 )
Ranked among companies with meaningful Net-margin (%) only.
PODD' s Net-margin (%) Range Over the Past 10 Years
Min: -43272  Med: -86.32 Max: -17.84
Current: -17.39
-43272
-17.84
ROE (%) -69.66
PODD's ROE (%) is ranked lower than
89% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. PODD: -69.66 )
Ranked among companies with meaningful ROE (%) only.
PODD' s ROE (%) Range Over the Past 10 Years
Min: -178.71  Med: -81.74 Max: -49.42
Current: -69.66
-178.71
-49.42
ROA (%) -17.17
PODD's ROA (%) is ranked lower than
74% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. PODD: -17.17 )
Ranked among companies with meaningful ROA (%) only.
PODD' s ROA (%) Range Over the Past 10 Years
Min: -98.54  Med: -44.51 Max: -17.45
Current: -17.17
-98.54
-17.45
ROC (Joel Greenblatt) (%) -73.23
PODD's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.36 vs. PODD: -73.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PODD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -437.09  Med: -194.65 Max: -65.62
Current: -73.23
-437.09
-65.62
Revenue Growth (3Y)(%) 16.80
PODD's Revenue Growth (3Y)(%) is ranked higher than
88% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. PODD: 16.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PODD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 19.95 Max: 101.6
Current: 16.8
0
101.6
EBITDA Growth (3Y)(%) -15.10
PODD's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. PODD: -15.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PODD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.6  Med: -34.05 Max: 25.9
Current: -15.1
-72.6
25.9
EPS Growth (3Y)(%) -1.90
PODD's EPS Growth (3Y)(%) is ranked lower than
62% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. PODD: -1.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PODD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -71  Med: -22.65 Max: 31.2
Current: -1.9
-71
31.2
» PODD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PODD Guru Trades in Q1 2015

Pioneer Investments 315,566 sh (+53.76%)
PRIMECAP Management 2,831,635 sh (+43.41%)
Mariko Gordon 2,037,999 sh (+34.36%)
Ken Fisher 9,588 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2015

PODD Guru Trades in Q2 2015

Steven Cohen 34,000 sh (New)
PRIMECAP Management 5,032,572 sh (+77.73%)
Pioneer Investments 341,232 sh (+8.13%)
Mariko Gordon 2,058,307 sh (+1.00%)
Ken Fisher 9,588 sh (unchged)
» More
Q3 2015

PODD Guru Trades in Q3 2015

Ken Fisher 16,963 sh (+76.92%)
PRIMECAP Management 5,194,669 sh (+3.22%)
Pioneer Investments 329,332 sh (-3.49%)
Steven Cohen 23,200 sh (-31.76%)
Mariko Gordon 1,323,195 sh (-35.71%)
» More
Q4 2015

PODD Guru Trades in Q4 2015

Ken Fisher 16,963 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 2000.00
PODD's Forward P/E is ranked lower than
100% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.04 vs. PODD: 2000.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 27.03
PODD's P/B is ranked lower than
100% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. PODD: 27.03 )
Ranked among companies with meaningful P/B only.
PODD' s P/B Range Over the Past 10 Years
Min: 3.13  Med: 14.02 Max: 1235
Current: 27.03
3.13
1235
P/S 5.01
PODD's P/S is ranked lower than
77% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. PODD: 5.01 )
Ranked among companies with meaningful P/S only.
PODD' s P/S Range Over the Past 10 Years
Min: 1.25  Med: 6.17 Max: 25.53
Current: 5.01
1.25
25.53
PFCF 1310.50
PODD's PFCF is ranked lower than
100% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.00 vs. PODD: 1310.50 )
Ranked among companies with meaningful PFCF only.
PODD' s PFCF Range Over the Past 10 Years
Min: 1310.5  Med: 1663.50 Max: 1890.5
Current: 1310.5
1310.5
1890.5
POCF 145.61
PODD's POCF is ranked lower than
95% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.50 vs. PODD: 145.61 )
Ranked among companies with meaningful POCF only.
PODD' s POCF Range Over the Past 10 Years
Min: 145.61  Med: 482.29 Max: 99999999.99
Current: 145.61
145.61
99999999.99
Current Ratio 3.27
PODD's Current Ratio is ranked higher than
62% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. PODD: 3.27 )
Ranked among companies with meaningful Current Ratio only.
PODD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.72 Max: 8.04
Current: 3.27
0.67
8.04
Quick Ratio 3.05
PODD's Quick Ratio is ranked higher than
70% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. PODD: 3.05 )
Ranked among companies with meaningful Quick Ratio only.
PODD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.32 Max: 7.56
Current: 3.05
0.56
7.56
Days Inventory 36.82
PODD's Days Inventory is ranked higher than
94% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.52 vs. PODD: 36.82 )
Ranked among companies with meaningful Days Inventory only.
PODD' s Days Inventory Range Over the Past 10 Years
Min: 28.31  Med: 61.70 Max: 111.63
Current: 36.82
28.31
111.63
Days Sales Outstanding 39.13
PODD's Days Sales Outstanding is ranked higher than
87% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.05 vs. PODD: 39.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
PODD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.85  Med: 73.05 Max: 1022
Current: 39.13
48.85
1022
Days Payable 36.26
PODD's Days Payable is ranked lower than
74% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. PODD: 36.26 )
Ranked among companies with meaningful Days Payable only.
PODD' s Days Payable Range Over the Past 10 Years
Min: 28.7  Med: 50.59 Max: 387.42
Current: 36.26
28.7
387.42

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 655.25
PODD's Price/Tangible Book is ranked lower than
100% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. PODD: 655.25 )
Ranked among companies with meaningful Price/Tangible Book only.
PODD' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.41  Med: 20.41 Max: 1123
Current: 655.25
3.41
1123
Price/Median PS Value 0.81
PODD's Price/Median PS Value is ranked higher than
63% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. PODD: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
PODD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.01 Max: 3.15
Current: 0.81
0.21
3.15
Earnings Yield (Greenblatt) (%) -2.58
PODD's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. PODD: -2.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PODD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.1  Med: 0.00 Max: 0
Current: -2.58
-5.1
0

More Statistics

Revenue(Mil) $297
EPS $ -0.91
Beta1.62
Short Percentage of Float6.85%
52-Week Range $24.95 - 40.21
Shares Outstanding(Mil)56.93

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 314 368 442 513
EPS($) -0.88 -0.53 -0.07 0.22
EPS without NRI($) -0.88 -0.53 -0.07 0.22

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:GOV.Germany,
Insulet Corp is a Delaware corporation formed in July 2000. The Company is engaged in the development, manufacturing and sale of OmniPod Insulin Management System. The OmniPod System is a disposable tubeless OmniPod worn on the body for approximately three days at a time. OmniPod Insulin Management System consists of disposable tubeless OmniPod worn on the body for approximatley three days at a time. The OmniPod System features two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. In October 2005 the Company began its commercial sale of OmniPod System in the United States. The Company sells OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through distribution partners. The OmniPod System is available in Europe through distribution partner, Ypsomed Distribution AG and in Canada through the distribution partner GlaxoSmithKline. The Company's sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among diabetes practitioners, academic medical centers, clinics, insulin-dependent diabetes patients, third-party payors, government agencies, and third-party distributors. The marketing strategy is to build awareness for the benefits of the OmniPod System through education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. As of December 31, 2013, the Company had obtained 15 issued United States patents, and had 8 additional pending U.S. patent applications. It has registered the trademarks OMNIPOD, INSULET and the OMNIPOD design with the United States Patent and Trademark Office on the Principal Register. The OmniPod System competes with Medtronic MiniMed, Animas Corporation, Tandem Diabetes Care, Inc. and Roche Diagnostics, a division of F. Hoffmann-La Roche, Ltd.
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Mariko Gordon's Trades In Q1 2015 Jun 12 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Dec 23 2009 
Insulet Corp. (PODD) COO Luis Malave sells 5,116 Shares Nov 24 2009 
Insulet Corp. (PODD) COO Luis Malave sells 6,000 Shares Nov 03 2009 

More From Other Websites
INSULET CORP Files SEC form 8-K, Regulation FD Disclosure Feb 02 2016
Insulet to Divest Neighborhood Diabetes Supplies Business Feb 02 2016
Insulet Corporation to Announce Fourth Quarter and Full Year 2015 Financial Results on February 25,... Jan 25 2016
Insulet Corporation to Announce Fourth Quarter and Full Year 2015 Financial Results on February 25,... Jan 25 2016
Insulet Raises Funds for Continued Diabetes Research Jan 19 2016
Insulet Raises Funds for Continued Diabetes Research Jan 19 2016
Insulet Corp. – Value Analysis (NASDAQ:PODD) : January 14, 2016 Jan 14 2016
Insulet Enters into Development Agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated... Jan 11 2016
Insulet Enters into Development Agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated... Jan 11 2016
[$$] MannKind Names Insider as CEO Jan 11 2016
Insulet Corp. breached its 50 day moving average in a Bearish Manner : January 11, 2016 Jan 11 2016
Insulet Corporation to Present at Upcoming Investor Conference Jan 11 2016
Insulet Corporation to Present at Upcoming Investor Conference Jan 11 2016
Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and... Jan 05 2016
Insulet Partners with Glooko as its Preferred Data Management Partner for OmniPod Patients and... Jan 05 2016
MannKind Gets Ol' Lump Of Coal For New CEO At Critical Time Dec 24 2015
MannKind's New Man In Charge Dec 24 2015
INSULET CORP Financials Dec 08 2015
Hedge Funds Are Selling Neustar Inc (NSR) Nov 29 2015
Opening Bell, November 16, 2015 Nov 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK